Tevogen Bio Holdings Inc. Market Cap ($38.55 Million)
Market Cap & Net Worth: Tevogen Bio Holdings Inc. (TVGN)
Tevogen Bio Holdings Inc. market cap. Tevogen Bio Holdings Inc. (NASDAQ:TVGN) has a market capitalization of $38.55 Million ($38.55 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #22651 globally and #4999 in its home market, demonstrating a -5.28% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Tevogen Bio Holdings Inc.'s stock price $5.92 by its total outstanding shares 6511540 (6.51 Million). Also see TVGN cash generation efficiency for how efficiently the company converts equity into cash flow.
Tevogen Bio Holdings Inc. Market Cap History (2024–2026)
Tevogen Bio Holdings Inc. market cap history from 2024 to 2026. Data shows growth from $6.90 Million to $38.55 Million (8.16% CAGR). Check today's stock price for Tevogen Bio Holdings Inc. for real-time trading data and today's change.
Index Memberships
Tevogen Bio Holdings Inc. is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.00% | #638 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #2129 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.83 Trillion | 0.00% | #248 of 263 |
Weight: Tevogen Bio Holdings Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Tevogen Bio Holdings Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Tevogen Bio Holdings Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore how fast is Tevogen Bio Holdings Inc. growing its equity to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of TVGN by Market Capitalization
Companies near Tevogen Bio Holdings Inc. in the global market cap rankings as of November 4, 2026. Also see TVGN total assets for a full breakdown of the balance sheet.
Key companies related to Tevogen Bio Holdings Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Tevogen Bio Holdings Inc. (2024–2026)
Market capitalization of Tevogen Bio Holdings Inc. from 2024 to today. Between 2024 and today, Tevogen Bio Holdings Inc.'s market cap moved from $6.90 Million to $ 38.55 Million, with a yearly change of 8.16%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $38.55 Million | +1687.98% |
| 2025 | $2.16 Million | -68.74% |
| 2024 | $6.90 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Tevogen Bio Holdings Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $38.55 Million USD |
| MoneyControl | $38.55 Million USD |
| MarketWatch | $38.55 Million USD |
| marketcap.company | $38.55 Million USD |
| Reuters | $38.55 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Tevogen Bio Holdings Inc.
Tevogen Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B… Read more